<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">White, Harvey D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Bivalirudin Not Superior to Unfractionated Heparin in Patients Receiving 600 mg Clopidogrel Prior to PCI</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">Bivalirudin failed to show a superior “net clinical benefit” compared with unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment 3 [ISAR-REACT 3] trial. However, bivalirudin reduced the rate of major and minor bleeding events in this patient population.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>